Masimo Corp. Hits New 52-Week High of $179.97, Reflecting Strong Growth

Masimo Corp., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 179.97 on June 8, 2026. This achievement underscores the company's robust performance, with a remarkable one-year return of 41.51%, significantly outpacing the S&P 500's 23.42% gain during the same period. The company boasts a market capitalization of USD 13,145 million and demonstrates strong financial health, highlighted by a return on equity of 29.07% and a low debt-to-equity ratio of 0.53. Masimo's ability to service its debt is further evidenced by a low debt-to-EBITDA ratio of 1.51 times. The firm has shown consistent growth, with net sales increasing at an annual rate of 5.95%. Additionally, Masimo has reported positive results for the last three consecutive quarters, with operating cash flow reaching USD 232 million and a net profit of USD 118.2 million in the most recent half-year. The company's high institutional holdings at 100% reflect strong confidence in its fundamentals, positioning it favorably within its industry.